ATA 2018 header

ATA 2018 Coverage

Molecular Testing May Prevent Unnecessary Treatment of Suspicious for Malignancy Thyroid Nodules

Molecular Testing May Prevent Unnecessary Treatment of Suspicious for Malignancy Thyroid Nodules

Molecular testing may identify benign disease in some patients with thyroid nodules classified as suspicious for malignancy, helping them avoid unnecessary treatment.

Lobectomy Rates for Low-Risk DTC Are Rising

Lobectomy Rates for Low-Risk DTC Are Rising

Adherence to the 2015 recommendation from ATA — to use lobectomy rather than complete thyroidectomy for low-risk differentiated thyroid cancer — is increasing.

Investigators Pinpoint Immune-Related Genes That Are Upregulated in ATC and PTC

Investigators Pinpoint Immune-Related Genes That Are Upregulated in ATC and PTC

Immune-related gene sets, including those for PD-L1/L2, are upregulated in ATC and PTC, but not in poorly differentiated disease or normal tissue.

MEK1/2 Inhibitor After RAI Fails to Improve Outcomes in High-Risk Nonmetastatic Thyroid Cancer

MEK1/2 Inhibitor After RAI Fails to Improve Outcomes in High-Risk Nonmetastatic Thyroid Cancer

The addition of selumetinib to radioactive iodine did not improve the complete remission rate among patients with high-risk nonmetastatic differentiated thyroid cancer.

Childhood Radiation-Induced Thyroid Cancer Does Not Lower All-Cause Survival

Childhood Radiation-Induced Thyroid Cancer Does Not Lower All-Cause Survival

Childhood radiation-induced thyroid cancer does not affect all-cause mortality compared with healthy individuals.

RET Inhibitor May Be Effective in RET-Altered Thyroid Cancers

RET Inhibitor May Be Effective in RET-Altered Thyroid Cancers

RET inhibitor LOXO-292 was well tolerated and demonstrated high antitumor activity against RET-altered thyroid cancers.

Malignancy Rates Higher in Children With Indeterminate Thyroid Nodules

Malignancy Rates Higher in Children With Indeterminate Thyroid Nodules

Malignancy was more common in children with thyroid nodules classified as indeterminate by BSRTC criteria compared with adults.

Soluble PD-L1 Levels Associated With Disease-Free Survival in Papillary Thyroid Cancer

Soluble PD-L1 Levels Associated With Disease-Free Survival in Papillary Thyroid Cancer

High serum soluble PD-L1 levels are associated with shorter disease-free survival among patients with papillary thyroid cancer.

Ethanol Sensitization May Improve RFA of Benign Thyroid Nodules

Ethanol Sensitization May Improve RFA of Benign Thyroid Nodules

Ethanol sensitization before radiofrequency ablation of benign thyroid nodules reduced time, ablation energy, and complications compared with conventional ablation.

Recombinant Human Thyrotropin Use Has No Effect on Outcomes After Radioiodine in DTC

Recombinant Human Thyrotropin Use Has No Effect on Outcomes After Radioiodine in DTC

Outcomes after radioiodine therapy are similar after preparation with either recombinant human thyrotropin or thyroid hormone withdrawal.

PRRA Fails to Improve Long-Term Outcomes in Low-Risk Papillary Thyroid Cancer

PRRA Fails to Improve Long-Term Outcomes in Low-Risk Papillary Thyroid Cancer

Postoperative radioiodine remnant ablation did not improve long-term outcomes among patients with low-risk papillary thyroid carcinoma.

US Centers Fail to Analyze Neck Lymph Nodes in Preoperative Ultrasounds for Thyroid Cancer

US Centers Fail to Analyze Neck Lymph Nodes in Preoperative Ultrasounds for Thyroid Cancer

Most imaging centers in the United States fail to analyze lateral neck lymph nodes during preoperative ultrasounds in patients with thyroid cancer.

BABA Robotic Thyroidectomy Determined to Be Safe and Effective

BABA Robotic Thyroidectomy Determined to Be Safe and Effective

The BABA robotic thyroidectomy technique appears to be safe, with excellent outcomes in benign and malignant thyroid disease.

First-Line Pembrolizumab Plus Chemoradiotherapy Found to Be Ineffective in Anaplastic Thyroid Cancer

First-Line Pembrolizumab Plus Chemoradiotherapy Found to Be Ineffective in Anaplastic Thyroid Cancer

Pembrolizumab plus chemoradiotherapy failed to improve survival and lead to unexpected deaths in a small study of patients with anaplastic thyroid cancer.

Thyroid irAEs Common With PD-L1 Inhibitors

Thyroid irAEs Common With PD-L1 Inhibitors

Thyroid-based immune-related adverse events are common among patients treated with PD-L1 inhibitors.

TRK Inhibitor Effective in TRK-Fusion Advanced Thyroid Cancer

TRK Inhibitor Effective in TRK-Fusion Advanced Thyroid Cancer

The TRK inhibitor larotrectinib was effective and well tolerated among patients with relapsed/refractory advanced TRK-fusion thyroid cancer.

Several Driver Genes, Tumor Suppressors Found to Be Mutated in Anaplastic Thyroid Cancer

Several Driver Genes, Tumor Suppressors Found to Be Mutated in Anaplastic Thyroid Cancer

Tumor suppressor and driver genes are frequently mutated in Korean patients with anaplastic thyroid cancer.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs